Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States

被引:66
|
作者
Rosen, Jennifer B. [1 ,2 ]
Thomas, Ann R. [3 ]
Lexau, Catherine A. [4 ]
Reingold, Art [5 ]
Hadler, Jim L. [6 ]
Harrison, Lee H. [7 ]
Bennett, Nancy M. [8 ]
Schaffner, William [9 ]
Farley, Monica M. [10 ,11 ]
Beall, Bernard W. [1 ]
Moore, Matt R. [1 ]
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA USA
[2] Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA
[3] Oregon Publ Hlth Div, Portland, OR USA
[4] Minnesota Dept Hlth, St Paul, MN USA
[5] Calif Emerging Infect Program, Oakland, CA USA
[6] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA
[7] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[8] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, Rochester, NY USA
[9] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA
[10] Emory Univ, Dept Med, Sch Med, Georgia Emerging Infect Program, Atlanta, GA 30322 USA
[11] VA Med Ctr, Atlanta, GA USA
关键词
STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; CHANGING EPIDEMIOLOGY; SEROTYPE; CHILDREN; ERA; IMMUNIZATION; SURVEILLANCE; INFECTION; EMERGENCE;
D O I
10.1093/cid/cir326
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Rates of invasive pneumococcal disease (IPD) varied among the United States before pneumococcal conjugate vaccine (PCV7) introduction. We compared trends in IPD rates among diverse US sites over 10 years since PCV7 introduction. Methods. Patients with IPD of all ages were identified through active population and laboratory-based surveillance in 8 geographic areas under continuous surveillance during 1998-2009. Isolates were serotyped. IPD incidence rates and percent changes were calculated by site, serotype group, age, and year. Results. Reductions in rates of IPD ranged, by site, from 19 to 29.9 cases per 100,000 population during 1998-1999 to 11.2-18.0 cases per 100,000 population during 2009 (rate reduction, 5.1-15.3 cases per 100,000 population). Reductions in IPD rates among children aged < 5 years ranged from 35.7 to 117.2 cases per 100,000 population across the sites. Reductions in rates of IPD due to PCV7 serotypes were seen in all age groups at all sites, ranging from 12 to 21.4 cases per 100,000 population during 1998-1999 to < 2 cases per 100,000 population during 2009 (92%-98% reductions). Serotype 19A rates ranged from 0.4 to 1.5 cases per 100,000 population during 1998-1999 to 1.3 to 3.4 cases per 100,000 population during 2009 (rate difference, 0.9-2.8 cases per 100,000 population); modest increases were observed for most age groups across the sites. Rates of IPD due to all other serotypes ranged from 6.3 to 10.3 cases per 100,000 population during 1998-1999 to 8.3-13.6 cases per 100,000 population during 2009 (rate difference, -0.4 to 5.7 cases per 100,000 population). Across the sites, the greatest rate increases were seen in the 50-64 and > 65 year age groups. Conclusions. Reductions in IPD due to vaccine serotypes were consistent across sites. Changes in serotype 19A and all other serotypes were variable. Although relative increases in non-vaccine type serotypes were large in some sites, absolute rate increases were small.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [1] Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
    Alexandrova Nikolova, Kristiana
    Andersson, Mikael
    Slotved, Hans-Christian
    Koch, Anders
    VACCINES, 2024, 12 (02)
  • [2] Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States
    Jacobs, David M.
    Yung, Francine
    Hart, Emily
    Nguyen, Melanie N. H.
    Shaver, Amy
    VACCINE, 2017, 35 (45) : 6160 - 6165
  • [3] Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States
    Tsai, Chiaojung Jillian
    Griffin, Marie R.
    Nuorti, J. Pekka
    Grijalva, Carlos G.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 (11) : 1664 - 1672
  • [4] Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines
    Tan, Tina Q.
    CLINICAL MICROBIOLOGY REVIEWS, 2012, 25 (03) : 409 - 419
  • [5] Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine
    Poehling, KA
    Talbot, TR
    Griffin, MR
    Craig, AS
    Whitney, CG
    Zell, E
    Lexau, CA
    Thomas, AR
    Harrison, LH
    Reingold, AL
    Hadler, JL
    Farley, MM
    Anderson, BJ
    Schaffner, W
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14): : 1668 - 1674
  • [6] Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine
    Dias, Ricardo
    Canica, Manuela
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2007, 51 (01): : 35 - 42
  • [7] Epidemiology of Invasive Pneumococcal Disease in Bangladeshi Children Before Introduction of Pneumococcal Conjugate Vaccine
    Saha, Samir K.
    Hossain, Belal
    Islam, Maksuda
    Hasanuzzaman, Md
    Saha, Shampa
    Hasan, Mohammad
    Darmstadt, Gary L.
    Chowdury, Mrittika
    El Arifeen, Shams
    Baqui, Abdullah H.
    Breiman, Robert F.
    Santosham, Mathuram
    Luby, Stephen P.
    Whitney, Cynthia G.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (06) : 655 - 661
  • [8] The conjugate vaccine and invasive pneumococcal disease
    Konradsen, HB
    Nokleby, H
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 714 - 715
  • [9] Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease
    Palmu, Arto A.
    Kilpi, Terhi M.
    Rinta-Kokko, Hanna
    Nohynek, Hanna
    Toropainen, Maija
    Nuorti, J. Pekka
    Jokinen, Jukka
    PEDIATRICS, 2015, 136 (01) : E22 - E27
  • [10] Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020
    Link-Gelles, Ruth
    Taylor, Thomas
    Moore, Matthew R.
    VACCINE, 2013, 31 (22) : 2572 - 2577